Idenix Pharmaceuticals, Inc.

Universitá Degli Studi Di Cagliari

Novartis Ag

David N Standring

Jean-Pierre Sommadossi

Vadim Bichko

Lin Qu

April Patty

Maria Seifer

Paolo LaColla

Paolo La Colla

April L Patty

Maria Seiffer

The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2'-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

2'-branched nucleosides and flaviviridae mutation

[object Object]

It has been discovered that &#x3b2;-L-2'-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a &#x3b2;-L-2&#x2032;-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a na&#xef;ve host is provided that includes administering a &#x3b2;-L-2&#x2032;-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a &#x3b2;-L-2&#x2032;-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

&#x3b2;-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies

The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2'-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from seine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (Sequence ID No. 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

2'-branched nucleosides and Flaviviridae mutation

Growing community of inventors

Milton, MA, United States of America

David N Standring